Pyxis Oncology is a clinical-stage biotechnology company developing next-generation immunotherapies that target the tumor microenvironment and modulate innate immune pathways. While primarily focused on oncology, the company's NLRP3 program has significant implications for neurodegenerative diseases, particularly [Parkinson's disease](/diseases/parkinsons-disease).
Company Profile
| Attribute | Value | |-----------|-------| | Founded | 2019 | | Headquarters | Boston, Massachusetts, USA | | CEO | Dr. Matthew Maurer | | IPO | Nasdaq (NASDAQ: PYXS), 2023 | | Focus | Immunotherapy, NLRP3 inhibitors | | Stage | Phase 1/Preclinical |
History
Pyxis Oncology was founded based on research from the Dana-Farber Cancer Institute and Massachusetts General Hospital. The company's initial focus was on cancer immunotherapy, particularly antibodies targeting CD47 and related "don't eat me" signals.
In 2022, Pyxis expanded its pipeline to include NLRP3 inflammasome inhibitors, recognizing the role of neuroinflammation in both cancer metastasis to the brain and primary neurodegenerative diseases.
Science and Technology
NLRP3 Program
Pyxis's NLRP3 program is distinct from its oncology focus but leverages the same scientific expertise:
Target: NLRP3 NACHT domain inhibition
Approach: Small molecules that block inflammasome assembly
Application: Both cancer immunotherapy and neurodegeneration
Pipeline Overview
...
Overview
Pyxis Oncology is a clinical-stage biotechnology company developing next-generation immunotherapies that target the tumor microenvironment and modulate innate immune pathways. While primarily focused on oncology, the company's NLRP3 program has significant implications for neurodegenerative diseases, particularly [Parkinson's disease](/diseases/parkinsons-disease).
Company Profile
| Attribute | Value | |-----------|-------| | Founded | 2019 | | Headquarters | Boston, Massachusetts, USA | | CEO | Dr. Matthew Maurer | | IPO | Nasdaq (NASDAQ: PYXS), 2023 | | Focus | Immunotherapy, NLRP3 inhibitors | | Stage | Phase 1/Preclinical |
History
Pyxis Oncology was founded based on research from the Dana-Farber Cancer Institute and Massachusetts General Hospital. The company's initial focus was on cancer immunotherapy, particularly antibodies targeting CD47 and related "don't eat me" signals.
In 2022, Pyxis expanded its pipeline to include NLRP3 inflammasome inhibitors, recognizing the role of neuroinflammation in both cancer metastasis to the brain and primary neurodegenerative diseases.
Science and Technology
NLRP3 Program
Pyxis's NLRP3 program is distinct from its oncology focus but leverages the same scientific expertise:
Target: NLRP3 NACHT domain inhibition
Approach: Small molecules that block inflammasome assembly
Application: Both cancer immunotherapy and neurodegeneration
PYX-002 is Pyxis's lead program for Parkinson's disease:
Mechanism: Direct NLRP3 inhibition
Selectivity: High selectivity for NLRP3 over other NLRs
BBB penetration: Optimized for brain exposure
Rationale: Block neuroinflammation without compromising anti-tumor immunity
The company's oncology expertise informs its understanding of immune modulation in the brain tumor microenvironment, which shares features with neuroinflammation in PD.
Technology Platform
Pyxis's technology platform includes:
Antibody engineering: Fc optimization for enhanced efficacy
Small molecule discovery: Structure-based design of NLRP3 inhibitors
Combination therapy: Rational combinations of immunotherapies
Clinical Development
Oncology Programs
PYX-001 (anti-CD47) is currently in Phase 1 clinical trials for solid tumors:
Mechanism: Blocks CD47-SIRPα "don't eat me" signal
Rationale: Enable macrophage phagocytosis of tumor cells